Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report

BACKGROUND Ovarian cancer is the most common malignant tumor of the female reproductive system,and the survival rate of patients with relapsed and refractory ovarian cancer is very low.CASE SUMMARY Here,we report a case of high-grade serous papillary adenocarcinoma of the ovary that was successfully treated with immunotherapy.Radical surgery and adjuvant chemotherapy for the 56-year-old patient were successful;however,her tumor relapsed.Subsequent second-line chemotherapy,targeted agents,and other treatments were ineffective,as the tumor continued to recur and metastasize.Anti-programmed cell death-1(PD-1)monotherapy(tislelizumab)completely alleviated the tumor,and the multiple metastatic tumors disappeared.To date,the patient has used anti-PD-1 for 32 months,experiencing no disease progression and maintaining good health without additional treatment.CONCLUSION This case suggests that anti-PD-1 immunotherapy may have long-term positive effects on outcomes in some refractory recurrent solid tumors.Further research is needed to identify patients most likely to respond to anti-PD-1 therapy.

Reconsideration of recurrence and metastasis in colorectal cancer

To discuss recurrence patterns and their significance in colorectal cancer.Preexisting medical hypotheses and the clinical phenomena of recurrence in colorectal cancer were evaluated and integrated.Colorectal cancer recurrence/metastasis consists of two types:recurrence from the activation of dormant cancer cells and recurrence from postoperative residual cancer cells.These two recurrences have their own unique mechanisms,biological behaviors,responses to therapy,and prognoses.For type 1 recurrences,surgical resection should be considered.Type 2 recurrences should be managed systematically in addition to surgical resection.The two types of colorectal cancer recurrence should be evaluated and managed separately.

Prospective clinical studies at the efficacy of brucea javanica oil,mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion

Objective:The aim of this study was to evaluate the effects and safety of brucea javanica oil,mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion.Methods:From July 2000 to May 2006,178 patients with primary superficial bladder cancer(Ta-1,G1-2) were divided into three groups after operation in random:57 patients in group A received perfusion of 60 mL 10% brucea javanica oil,and 66 patients in group B received perfusion of 20 mg mitomycin while 55 patients in group C received perfusion of 120 mg BCG.Eighteen perfusions per patient were carried out regularly a week after operation.Patients were followed up for clinical,analytical and cystoscopic evaluations every 3 months for 2 years.The tumor relapse rates and side effects after treatment were evaluated.Results:The relapse rate was 14.04%(8/57),34.85%(23/66) and 18.18%(10/55) in group A,B and C respectively.The relapse rate in group A was obviously lower than that in group B(χ2 = 6.17,P < 0.05).Disease free interval in group A was significantly different from that in group B(F = 7.03,P < 0.05).Side effect in group A(12.28%) was observably lower than that in group B(43.94%) and group C(83.64%)(χ2AB = 15.72,P < 0.01;χ2AC = 55.34,P < 0.01).Conclusion:Perfusion of 10% brucea javanica oil after operation is safer and more effective in preventing superficial bladder tumour relapse and worth for popularizing.

Current updates in management of relapsed/refractory small cell lung cancer

Small cell lung cancer(SCLC)is an aggressive subtype of neuroendocrine tumor.It is characterized by a rapid doubling time and early development of metastatic disease.Despite being responsive to initial chemotherapy,most of the patients will have relapse of the disease within a few months.The prognosis of SCLC is dismal with a 5-year survival rate of less than 5%.For that reason,management of SCLC has been an active area of research.The utilization of immunotherapy has provided promising results in treatment of SCLC in the front-line setting.Therefore,utilization of immunotherapy and targeted therapy is being studied in the setting of relapsed/refractory disease,and currently,different clinical trials are exploring new drugs and further options.In this review,we will explore the latest updates in management of relapsed/refractory SCLC.